Skip to main content
Clinical Trials/NCT04124978
NCT04124978
Completed
Not Applicable

Evaluation of the Effectiveness of Direct to Consumer Mandibular Advancement Devices as an Adjunct for the Treatment of Mild to Moderate Obstructive Sleep Apnoea (OSA)

Singapore General Hospital1 site in 1 country32 target enrollmentJuly 21, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obstructive Sleep Apnea
Sponsor
Singapore General Hospital
Enrollment
32
Locations
1
Primary Endpoint
Epworth sleepiness score (ESS)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Use of mandibular advancement devices(MADs) in the treatment of Obstructive Sleep Apnea is established, however this is hampered by high costs, long wait times and non-assured success in the local Asian setting. There are few studies which look at the use of prefabricated thermoplastic mandibular devices with a titratable component and its efficacy. In addition, it is direct-to-consumer and an economical option, thus there may be a role in the use of such devices to better select patients who may benefit and are thinking of using MADs.

The investigators aim to evaluate the effectiveness of the use of Prefabricated adjustable thermoplastic mandibular advancement devices(PAT-MADs)(MyTAP) in the treatment of OSA and its role for predicting treatment success in an Asian population.

Detailed Description

Mandibular advancement devices (MAD) serve as an adjunct to the treatment of snoring as well as mild-moderate OSA. It is widely accepted that upper airway muscle activity decreases during sleep, leading to increased collapsibility of the pharyngeal tissues, mandibular opening and posterior displacement of the tongue. These changes result in narrowing of the oropharyngeal and hypopharyngeal airway (Hudgel 1992). Their primary action is to advance the mandible and tongue to increase the upper airway size. Recent systemic review on the effectiveness of MAD in treating OSA by Torres et al in the Laryngoscope showed that 16 out of 18 large scale studies showed significant improvement in Apnea-Hypopnea index (AHI). There are a wide variety of MAD commercially available and they can be broadly divided into custom made vs prefabricated makes as well as titratable versus non-titratable types. It is shown that custom made, titratable fitted MADs are superior in efficacy as compared to their counterpart models. However, high cost, delayed waiting times and multiple clinic visits are required for patients to be fitted with custom MADs by a professional orthodontist. Newly developed direct to consumer thermoplastic MADs (MyTap) brings the benefit of mouldable bite and form "custom" fit with the option of titration to the user at a lower cost, technical ease of use and fit in the clinic setting. Participants who are diagnosed with simple snoring or mild to moderate OSA are able to trial use thermoplastic MADs to have a sense of the level of comfort and effectiveness MAD can bring to improve their OSA, serving as a bridging device prior to committing to the use of custom made MAD. The investigators aim to evaluate the effectiveness of the use of Prefabricated adjustable thermoplastic mandibular advancement devices(PAT-MADs)(MyTAP) in the treatment of OSA and its role for predicting treatment success, compliance and comfort in an Asian population.

Registry
clinicaltrials.gov
Start Date
July 21, 2017
End Date
April 23, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18years old and above
  • English competency
  • Formal diagnosis of mild-moderate OSA on PSG
  • Ability to provide informed consent

Exclusion Criteria

  • diagnosed severe OSA
  • evidence of central sleep apnea events
  • dental conditions which preclude proper use of the MAD
  • treatment with other devices (e.g. tongue retainers, PAP therapy)
  • pregnancy
  • known allergic reactions to the components of the study product were excluded from the trial.

Outcomes

Primary Outcomes

Epworth sleepiness score (ESS)

Time Frame: 3 months

Epworth sleepiness score measures the level of sleepiness in a participant. Minimum value of 0 to a maximum level of 24, whereby the higher the value, the sleepier the participant.

Pittsburgh sleep quality index (PSQI)

Time Frame: 3 months

Quality of life survey made up of 19 self rated questions which assesses the quality of 7 different aspects of sleep in participants with sleep disorders. Minimum value is 0 and maximum value is 21, where the higher the global value, the more severe the difficulties in different aspects of sleep.

Apnea-Hypopnea Index (AHI)

Time Frame: 3 months

apnea-hypopnea index

Oxygen disturbance index (ODI)

Time Frame: 3 months

Oxygen disturbance index

Lowest oxygen saturation (Lsat)

Time Frame: 3 months

Lowest oxygen saturation

Apnea index (AI)

Time Frame: 3 months

apnea index

Hypopnea index (HI)

Time Frame: 3 months

Hypopnea index

Abbreviated functional outcomes of sleep questionnaire (FOSQ-10)

Time Frame: 3 months

Quality of life survey made of up 10 self rated questions which assess the quality of sleep in participants with sleep disorders. Minimum value is 0 and maximum value is 40, where the lower the global value, the worse off the quality of sleep.

Secondary Outcomes

  • Predicting future use(3 months)

Study Sites (1)

Loading locations...

Similar Trials